Paragon 28(R) launches a cut guide system specifically to control bone resection while addressing IM reduction in a Lapidus procedure
ENGLEWOOD, Colo., July 5, 2018 -- (Healthcare Sales & Marketing Network) -- Since its inception, Paragon 28® has obsessed over every aspect of foot and ankle surgery. Committed to creating tailored solutions to improve surgical outcomes, Paragon 28&re... Devices, Orthopaedic, Product Launch Paragon 28, Lapidus Cut Guide (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 6, 2018 Category: Pharmaceuticals Source Type: news

FDA Clears The Way: Lipogems' Receives FDA Clearance For Microfragmented Adipose Tissue System Utilizing Body's Own Fat To Support Tissue Repair In Orthopaedic And Arthroscopic Surgeries
NORCROSS, Ga., July 5, 2018 -- (Healthcare Sales & Marketing Network) -- Lipogems, a leader in medical technologies for orthopaedic physicians, announced U.S. Food and Drug Administration (FDA) clearance of the company's Lipogems Microfragmented Adipose T... Regenerative Medicine, Orthopaedic, FDA Lipogems, Microfragmented Adipose Tissue, Transplant (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 6, 2018 Category: Pharmaceuticals Source Type: news

BioArctic Announces Positive Topline Results of BAN2401 Phase 2b at 18 Months in Early Alzheimer's Disease
The full 18 month analysis of the 856 patient BAN2401 Phase 2b clinical study in early Alzheimer's disease demonstrated statistically significant and dose-dependent slowing in clinical decline and reduction of amyloid beta accumulated in the brain. Firs... Biopharmaceuticals, Neurology BioArctic, anti-amyloid, amyloid, Alzheimer's disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 6, 2018 Category: Pharmaceuticals Source Type: news

ITUS Corporation Announces Second Commercial Focus for Cchek(TM) will be Breast Cancer
SAN JOSE, Calif., July 6, 2018 -- (Healthcare Sales & Marketing Network) -- ITUS Corporation (NASDAQ: ITUS) today announced that due to the significance of positive results as well as strong commercial interest, it has selected breast cancer as the next c... Diagnostics, Oncology ITUS Corporation, Cchek , liquid biopsy, prostate cancer, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 6, 2018 Category: Pharmaceuticals Source Type: news

Boston Scientific to Acquire Cryterion Medical, Inc.
Company to expand atrial fibrillation ablation therapy offerings with innovative cryoballoon platform MARLBOROUGH, Mass., July 5, 2018 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (NYSE: BSX) today announced a definitive a... Devices, Cardiology, Mergers & Acquisitions Boston Scientific, Cryterion Medical, cryoablation, atrial fibrillation (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 5, 2018 Category: Pharmaceuticals Source Type: news

5-Year Outcomes Following A HIFU Focal Therapy Study Demonstrate Impressive Disease Control And Low Side Effect Profile For Prostate Cancer Patients In The U.K.
Sonablate® HIFU used in study to treat clinically significant nonmetastatic prostate cancer achieves complete pad-free urinary continence in 98% of men. CHARLOTTE, N.C., July 5, 2018 -- (Healthcare Sales & Marketing Network) -- SonaCare Medical, th... Devices, Oncology SonaCare Medical, HIFU , Sonablate, prostate cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 5, 2018 Category: Pharmaceuticals Source Type: news

New England Journal of Medicine Publishes Results from Pivotal Study of TEGSEDI(TM) (inotersen) for the Treatment of Hereditary ATTR Amyloidosis
TEGSEDI treatment demonstrated substantial improvement in measures of neuropathy progression and quality of life CARLSBAD, Calif., and CAMBRIDGE, Mass., July 5, 2018 -- (Healthcare Sales & Marketing Network) -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS... Biopharmaceuticals, Neurology Ionis Pharmaceuticals, Akcea Therapeutics, TEGSEDI, inotersen, hATTR (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 5, 2018 Category: Pharmaceuticals Source Type: news

Adlai Nortye Raises $53M in Series B
HANGZHOU, China, July 5, 2018 -- (Healthcare Sales & Marketing Network) -- Adlai Nortye Biopharma Co., Ltd. ("Adlai Nortye" or "the Company"), a biopharmaceutical company, announced that it has raised $53 million in a Series B financin... Biopharmaceuticals, Oncology, Venture Capital Adlai Nortye Biopharma, Reolysin (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 5, 2018 Category: Pharmaceuticals Source Type: news

Theratechnologies Submits Novel Single-Vial Formulation of EGRIFTA(R) (Tesamorelin for Injection) for FDA Approval
MONTREAL, July 04, 2018 -- (Healthcare Sales & Marketing Network) -- Theratechnologies Inc. (Theratechnologies) (TSX:TH) today announced that it has filed a supplemental new drug application (sNDA) with the Food and Drug Administration (FDA) for a single-v... Biopharmaceuticals, HIV/AIDS, FDA Theratechnologies, EGRIFTA, Tesamorelin (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 4, 2018 Category: Pharmaceuticals Source Type: news

Sorrento Acquires the Sofusa(TM) Lymphatic Delivery Platform for Immune-Oncology (I-O) Antibody Therapeutics
SAN DIEGO, July 03, 2018 -- (Healthcare Sales & Marketing Network) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE) ("Sorrento") announced today that it acquired the Sofusa™ lymphatic delivery technology platform from Kimberly-Clark Corporation for ... Biopharmaceuticals, Oncology, Drug Delivery, Acquisitions Sorrento Therapeutics, Kimberly-Clark, Sofusa, Lymphatic Delivery (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 3, 2018 Category: Pharmaceuticals Source Type: news

Juniper Pharmaceuticals Signs Definitive Agreement to be Acquired by Catalent, Inc. for $11.50 Per Share in Cash
BOSTON, July 3, 2018 -- (Healthcare Sales & Marketing Network) -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP), a diversified healthcare company with core businesses of its CRINONE® (progesterone gel) franchise and fee-for-service contract development ... Biopharmaceuticals, Mergers & Acquisitions Juniper Pharmaceuticals, Catalent , CRINONE, progesterone gel (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 3, 2018 Category: Pharmaceuticals Source Type: news

MabVax Therapeutics Grants Exclusive Sublicense to Y-mAbs Therapeutics for Patented Neuroblastoma Vaccine
SAN DIEGO, July 3, 2018 -- (Healthcare Sales & Marketing Network) -- MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical stage oncology drug development company has granted to Y-mAbs Therapeutics, Inc., a privately held clinical stage biopharmac... Biopharmaceuticals, Oncology, Licensing MabVax Therapeutics, Y-mAbs Therapeutics, neuroblastoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 3, 2018 Category: Pharmaceuticals Source Type: news

UK’s NICE Publishes a Medtech Innovation Briefing on PICO(TM) for the Prophylactic Use in Surgically Closed Incisions to Reduce Surgical Site Complications
LONDON and NEW YORK, July 3, 2018 -- (Healthcare Sales & Marketing Network) -- Smith & Nephew (LSE: SN) (NYSE: SNN), the global medical technology business, announces that the UK's National Institute for Health and Care Excellence (NICE) has issued a Medt... Devices, Surgery, Wound Care Smith & Nephew, PICO , Negative Pressure Wound Therapy, NPWT (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 3, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in People With Metastatic or Locally Advanced Triple Negative Breast Cancer
First Phase III immunotherapy study to demonstrate a statistically significant progression-free survival (PFS) improvement in intention-to-treat (ITT) and PD-L1 positive first-line metastatic triple negative breast cancer (TNBC) populations Encouraging ... Biopharmaceuticals, Oncology Genentech, Roche Group, TECENTRIQ, atezolizumab, triple negative, breast cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 2, 2018 Category: Pharmaceuticals Source Type: news

Ultragenyx Announces Positive CHMP Opinion for Mepsevii(TM) (vestronidase alfa) For the Treatment of Mucopolysaccharidosis VII
NOVATO, Calif., June 29, 2018 -- (Healthcare Sales & Marketing Network) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agenc... Biopharmaceuticals, Regulatory Ultragenyx Pharmaceutical, Mepsevii, vestronidase alfa, Mucopolysaccharidosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 29, 2018 Category: Pharmaceuticals Source Type: news

Ultragenyx Announces Positive CHMP Opinion for Mepsevii™ (vestronidase alfa) For the Treatment of Mucopolysaccharidosis VII
NOVATO, Calif., June 29, 2018 -- (Healthcare Sales & Marketing Network) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agenc... Biopharmaceuticals, Regulatory Ultragenyx Pharmaceutical, Mepsevii, vestronidase alfa, Mucopolysaccharidosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 29, 2018 Category: Pharmaceuticals Source Type: news

Amneal Announces Favorable Ruling Regarding Patent Validity for Zomig(R) (zolmitriptan) Nasal Spray
BRIDGEWATER, N.J., June 29, 2018 -- (Healthcare Sales & Marketing Network) -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that a panel of three Circuit Judges of the U.S. Court of Appeals for the Federal Circuit has affirmed the March 30, 20... Biopharmaceuticals, Generics, Litigation Amneal Pharmaceuticals, AstraZeneca, Lannett, Zomig, zolmitriptan (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 29, 2018 Category: Pharmaceuticals Source Type: news

Intec Pharma Appoints William Bradley Hayes to Board of Directors
Former LabCorp CFO Brings Wealth of Financial Experience JERUSALEM, June 29, 2018 -- (Healthcare Sales & Marketing Network) -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: NTEC) ("Intec" or "the Company") today announces the appointment ... Biopharmaceuticals, Drug Delivery, Personnel Intec Pharma, Accordion Pill (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 29, 2018 Category: Pharmaceuticals Source Type: news

I-Mab Successfully Raised USD 220 Million in Series C Funding
SHANGHAI, June 29, 2018 -- (Healthcare Sales & Marketing Network) -- I-Mab Biopharma, a company focusing on innovative Biologics in therapeutic areas of immuno-oncology and immuno-inflammation, announced the completion of Series C financing for USD 220 mi... Biopharmaceuticals, Oncology, Venture Capital I-Mab Biopharma, Genexine, HyLeukin, immunotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 29, 2018 Category: Pharmaceuticals Source Type: news

Edwards Comments On CMS Initiation Of National Coverage Analysis For TAVR
IRVINE, Calif., June 28, 2018 -- (Healthcare Sales & Marketing Network) -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today commented on the anno... Devices, Interventional, Cardiology, Reimbursement Edwards Lifesciences, transcatheter, aortic valve, TAVR (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 28, 2018 Category: Pharmaceuticals Source Type: news

Avella Selected by Array BioPharma Inc. to distribute BRAFTOVI(TM) (encorafenib) and MEKTOVI(R) (binimetinib)
The specialty pharmacy will give patients access to this important new FDA-approved combination therapy for patients with advanced BRAF melanoma PHOENIX, June 28, 2018 -- (Healthcare Sales & Marketing Network) -- Avella has announced that it will distr... Biopharmaceuticals, Oncology, Distribution Avella, Array BioPharma, BRAFTOVITM, encorafenib, MEKTOVI, binimetinib (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 28, 2018 Category: Pharmaceuticals Source Type: news

Renovis Surgical Receives FDA Clearance for Tesera Trabecular Technology(TM) Hyperlordotic ALIF Interbody Spinal Fusion System
REDLANDS, Calif. and AUSTIN, Texas, June 28, 2018 -- (Healthcare Sales & Marketing Network) -- Renovis Surgical Technologies, Inc. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the Tesera&... Devices, Orthopaedic, Neurosurgery, FDA Renovis Surgical Technologies, Tesera, Hyperlordotic, Spinal Fusion (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 28, 2018 Category: Pharmaceuticals Source Type: news

Thermo Fisher Scientific Expands Oncomine Immuno-Oncology Assay Portfolio
Oncomine TCR Beta-SR Assay for next-generation sequencing enables site-specific interrogation for T-cell receptor applications CARLSBAD, Calif., June 28, 2018 -- (Healthcare Sales & Marketing Network) -- Thermo Fisher Scientific today announced the lau... Diagnostics, Product Launch Thermo Fisher Scientific, Oncomine, TCR Beta-SR Assay (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 28, 2018 Category: Pharmaceuticals Source Type: news

Corporate Biotech Executive Mark Germain Joins BiondVax's Board of Directors
NESS ZIONA, Israel, June 28, 2018 -- (Healthcare Sales & Marketing Network) -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), developer of M-001, a clinical phase Universal Influenza Vaccine candidate, announced today the appointment of Mr. Mark Germain a... Biopharmaceuticals, Personnel BiondVax Pharmaceuticals, influenza, influenza vaccine, flu vaccine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 28, 2018 Category: Pharmaceuticals Source Type: news

Lilly Announces Positive Top-Line Results for Second Phase 3 Study of Taltz(R) (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) for TNF Inhibitor-Experienced Patients
INDIANAPOLIS, June 28, 2018 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today that Taltz® (ixekizumab) met the primary and major secondary endpoints in COAST-W, a Phase 3 study evaluating the safety and eff... Biopharmaceuticals Eli Lilly, Taltz, ixekizumab, Ankylosing Spondylitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 28, 2018 Category: Pharmaceuticals Source Type: news

BrainStorm Strengthens Executive Management Team with the Appointment of Susan Ward, Ph.D. and Joseph Petroziello
Susan Ward, Ph.D. (Pfizer) Appointed Head of Clinical Operations Joe Petroziello (Juno Therapeutics) Appointed VP of Scientific & Corporate Communications NEW YORK and PETACH TIKVAH, Israel, June 28, 2018 -- (Healthcare Sales & Marketing Network) --... Regenerative Medicine, Personnel BrainStorm Cell Therapeutics, stem cell therapeutics, stem cell, NurOwn (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 28, 2018 Category: Pharmaceuticals Source Type: news

Biohaven Expands Rimegepant Development Program to Include New Prevention of Migraine Phase 3 Trial and Highlights Key Late-Breaking Presentations at American Headache Society (AHS) Annual Scientific Meeting
Phase 3 clinical trial to evaluate rimegepant as a preventive therapy for migraine expected to begin by the fourth quarter of 2018 Late-breaking oral presentation at AHS to present pivotal Phase 3 trial data showing single-dose rimegepant provides rapid... Biopharmaceuticals Biohaven Pharmaceutical, rimegepant, migraine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 28, 2018 Category: Pharmaceuticals Source Type: news

Lupin and Mylan Partner to Commercialize Enbrel(R) (Etanercept) Biosimilar
MUMBAI, India and HERTFORDSHIRE, England and PITTSBURGH, June 28, 2018 -- (Healthcare Sales & Marketing Network) -- Pharma major Lupin Limited (Lupin) and global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that the two companies will p... Biopharmaceuticals, Generics Mylan, Lupin, biosimilar, Enbrel, etanercept (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 28, 2018 Category: Pharmaceuticals Source Type: news

Revive Therapeutics Announces FDA Grants Orphan Drug Designation for Cannabidiol in the Treatment of Autoimmune Hepatitis
TORONTO, June 27, 2018 -- (Healthcare Sales & Marketing Network) -- Revive Therapeutics Ltd. (TSX VENTURE:RVV) (OTCQB:RVVTF) (FSE:31R) ("Revive" or the "Company"), a company focused on the research, development and commercialization of ... Biopharmaceuticals, FDA Revive Therapeutics, cannabinoid, autoimmune hepatitis, hepatitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 27, 2018 Category: Pharmaceuticals Source Type: news

Beckman Coulter Diagnostics Receives U.S. FDA 510(k) Clearance for High- sensitivity Access hsTnI Assay
First high-sensitivity troponin I assay available in the United States enables clinicians to provide efficiency improvements in cardiac patient management BREA, Calif., June 27, 2018 -- (Healthcare Sales & Marketing Network) -- Beckman Coulter Diagnos... Diagnostics, Cardiology, FDA Beckman Coulter, troponin, myocardial infarction (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 27, 2018 Category: Pharmaceuticals Source Type: news

Adicet Bio appoints Stewart Abbot, Ph.D. as Chief Scientific Officer
MENLO PARK, Calif., June 27, 2018 -- (Healthcare Sales & Marketing Network) -- Adicet Bio, Inc. ("Adicet"), a biopharmaceutical company focused on the development of next-generation immunotherapies, announced today that it has appointed Stewart ... Biopharmaceuticals, Oncology, Personnel Adicet Bio, universal immune cell therapies, immunotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 27, 2018 Category: Pharmaceuticals Source Type: news

ANI Pharmaceuticals Announces Launch of Cholestyramine for Oral Suspension USP
BAUDETTE, Minn., June 27, 2018 -- (Healthcare Sales & Marketing Network) -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Cholestyramine for Oral Suspension USP, 4g/dose, in cans. The current annual U.S. market ... Biopharmaceuticals, Product Launch ANI Pharmaceuticals, cholestyramine, hypercholesterolemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 27, 2018 Category: Pharmaceuticals Source Type: news

AcelRx receives European Commission approval for DZUVEO(TM)
AcelRx's DZUVEO receives EU approval for management of acute moderate to severe pain in medically monitored settings REDWOOD CITY, Calif., June 27, 2018 -- (Healthcare Sales & Marketing Network) -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx o... Biopharmaceuticals, Drug Delivery, Regulatory AcelRx Pharmaceuticals, DZUVEO, DSUVIA , sufentanil, sublingual (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 27, 2018 Category: Pharmaceuticals Source Type: news

Carisma Therapeutics Announces a $53 Million Series A Financing to Develop Novel CAR Macrophage Cellular Immunotherapy
Initial applications to focus on the treatment of solid tumor malignancies Clinical trials expected to begin in 2019 PHILADELPHIA, June 27, 2018 -- (Healthcare Sales & Marketing Network) -- Carisma Therapeutics Inc., formerly CARMA Therapeutics, a p... Biopharmaceuticals, Venture Capital Carisma Therapeutics, macrophage, immunotherapeutics, immunotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 27, 2018 Category: Pharmaceuticals Source Type: news

Relievant Announces Completion of $58M Series E Financing to Support US Commercialization
Company to open corporate headquarters in Minneapolis, MN MINNEAPOLIS, June 26, 2018 -- (Healthcare Sales & Marketing Network) -- Relievant Medsystems, a privately-held medical device company developing minimally-invasive solutions for chronic low back ... Devices, Orthopaedic, Neurosurgery, Venture Capital Relievant Medsystems, low back pain, Intracept, basivertebral nerve (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 26, 2018 Category: Pharmaceuticals Source Type: news

Salix And US WorldMeds Enter Into Exclusive Co-Promotion Agreement For Opioid Withdrawal Treatment LUCEMYRA(TM) (lofexidine)
Salix Sales Force to Begin Promoting LUCEMYRA to Primary Care and Pain Management Physicians LUCEMYRA is the First and Only Non-Opioid Medication Approved for Mitigation of Opioid Withdrawal Symptoms 08:00 ET from US WorldMeds LOUISVILLE, Ky. and... Biopharmaceuticals, Distribution US WorldMeds, Salix Pharmaceuticals, LUCEMYRA, lofexidine, Opioid Withdrawal (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 26, 2018 Category: Pharmaceuticals Source Type: news

Sechrist Industries And Dartmouth's Geisel School Of Medicine Work Together To Bring Hyperbaric Oxygen Therapy To Tanzania
ANAHEIM, Calif., June 26, 2018 -- (Healthcare Sales & Marketing Network) -- Sechrist Industries, Inc. has partnered with Jay Buckey, MD, Professor of Medicine at Dartmouth College's Geisel School of Medicine, to bring Hyperbaric Oxygen Therapy (HBOT) to T... Devices Sechrist Industries, hyperbaric oxygen, hyperbaric therapy, hyperbaric chamber (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 26, 2018 Category: Pharmaceuticals Source Type: news

AbbVie and Calico Announce Extension of Groundbreaking Collaboration
Extension builds on collaboration established in 2014 Collaboration focuses on aging and age-related diseases, including neurodegeneration and cancer NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., June 26, 2018 -- (Healthcare Sales & Marketing ... Biopharmaceuticals, Neurology, Oncology AbbVie, Calico , neurodegeneration, cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 26, 2018 Category: Pharmaceuticals Source Type: news

InfuSystem Holdings, Inc. Selected as an Official Distributor of CADD(R) Infusion Therapy Products by Smiths Medical
MADISON HEIGHTS, Mich., June 26, 2018 -- (Healthcare Sales & Marketing Network) -- InfuSystem Holdings, Inc. (NYSE American: INFU) ("InfuSystem" or the "Company"), a leading national provider of infusion pumps and related services for ... Devices, Distribution InfuSystem Holdings, Smiths Medical, CADD infusion (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 26, 2018 Category: Pharmaceuticals Source Type: news

Caris Life Sciences Expands Management Team
Meeting the needs of a complex and growing market Brian Brille, experienced financial services executive joins as Vice Chairman, leading corporate and business development, M&A and capital markets Seasoned healthcare executives Michael Sullivan and N... Diagnostics, Personnel Caris Life Sciences, ADAPT Biotargeting System, precision medicine (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 26, 2018 Category: Pharmaceuticals Source Type: news

IMBRUVICA(R) (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenström's Macroglobulinemia (WM), A Rare Form of Blood Cancer
The filing is based on data from the Phase 3 iNNOVATE study, which suggest that IMBRUVICA plus rituximab may improve outcomes across all lines of Waldenström's macroglobulinemia (WM) treatment, including patients with prior lines of therapy and variou... Biopharmaceuticals, Oncology, FDA AbbVie, IMBRUVICA, ibrutinib, Waldenström's Macroglobulinemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 25, 2018 Category: Pharmaceuticals Source Type: news

Beckman Coulter Files a 510(k) Submission with the FDA for Its Early Sepsis Indicator*
Offered as part of a routine CBC with differential test, the hematology-based solution is intended to alert emergency department clinicians to sepsis or the possibility of sepsis earlier than any other indicator BREA, Calif., June 25, 2018 -- (Healthca... Diagnostics, FDA Beckman Coulter, Early Sepsis Indicator, Sepsis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 25, 2018 Category: Pharmaceuticals Source Type: news

Radiation oncologists urge Congress to protect patient access to cancer care
WASHINGTON, June 25, 2018 -- (Healthcare Sales & Marketing Network) -- Radiation oncologists from across the United States will visit Capitol Hill tomorrow to urge Congress to support policies that safeguard cancer patients' access to high-quality, high-va... Devices, Oncology, Reimbursement American Society for Radiation Oncology, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 25, 2018 Category: Pharmaceuticals Source Type: news

Cronos Group Inc. Announces Exclusive Distribution Agreement with Delfarma in Poland
TORONTO, June 25, 2018 -- (Healthcare Sales & Marketing Network) – Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos Group" or the "Company"), is pleased to announce that it has entered into a strategic distribution partnership wi... Biopharmaceuticals, Distribution Cronos Group, Delfarma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 25, 2018 Category: Pharmaceuticals Source Type: news

Akero Therapeutics Closes $65 Million Series A Financing to Advance New Treatments for Serious Metabolic Diseases
Financing led by Apple Tree Partners, Atlas Venture, venBio Partners and Versant Ventures Company Announces Licensing Agreement with Amgen CAMBRIDGE, Mass., June 25, 2018 -- (Healthcare Sales & Marketing Network) -- Akero Therapeutics, Inc., a biote... Biopharmaceuticals, Licensing, Venture Capital Akero Therapeutics, Amgen, non-alcoholic steatohepatitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 25, 2018 Category: Pharmaceuticals Source Type: news

DelMar Pharmaceuticals Appoints World-Renowned Molecular Biologist Dr. Napoleone Ferrara to Board of Directors
VANCOUVER, British Columbia and MENLO PARK, Calif., June 25, 2018 -- (Healthcare Sales & Marketing Network) -- DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the developm... Biopharmaceuticals, Personnel DelMar Pharmaceuticals, angiogenesis, VEGF (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 25, 2018 Category: Pharmaceuticals Source Type: news

FDA Authorizes FRESCA Medical To Market New Positive Airway Pressure Delivery System To Treat Sleep Apnea
Novel Low-Flow Technology Has Demonstrated Efficacy in Obstructive Sleep Apnea Patients SAN CLEMENTE, Calif., June 25, 2018 -- (Healthcare Sales & Marketing Network) -- FRESCA Medical, Inc., a privately held sleep solutions and connected health company... Devices, FDA FRESCA Medical, CURVE System, Positive Airway Pressure, sleep apnea (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 25, 2018 Category: Pharmaceuticals Source Type: news

Nordic Nanovector Appoints Eduardo Bravo as Chief Executive Officer
OSLO, 25 June, 2018 -- (Healthcare Sales & Marketing Network) -- Nordic Nanovector ASA (OSE: NANO) announces that Eduardo Bravo has been appointed as its Chief Executive Officer. Mr. Bravo brings more than 25 years' experience in the biopharmaceutical ... Biopharmaceuticals, Oncology, Personnel Nordic Nanovector, Betalutin, non-Hodgkin's lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 25, 2018 Category: Pharmaceuticals Source Type: news

William A. Haseltine, PhD Joins Grace Therapeutics' Board of Directors
Pioneering Scientist and Former CEO of Human Genome Sciences Brings Key Expertise to Grace's Board EAST BRUNSWICK, N.J., June 22, 2018 -- (Healthcare Sales & Marketing Network) -- Grace Therapeutics, a clinical stage biopharmaceutical company focused o... Biopharmaceuticals, Neurology, Personnel Grace Therapeutics (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 22, 2018 Category: Pharmaceuticals Source Type: news

Elizabeth O'Farrell Named to PDL BioPharma's Board of Directors
INCLINE VILLAGE, Nev., June 22, 2018 -- (Healthcare Sales & Marketing Network) -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) announced today that retired Eli Lilly and Company executive Elizabeth G. O'Farrell has been ... Biopharmaceuticals, Devices, Personnel PDL BioPharma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 22, 2018 Category: Pharmaceuticals Source Type: news